ArticleJournal of neuro-oncology2010
Multiple sclerosis attacks triggered by hyperprolactinemia.
Article in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 23 citations in OpenAlex.
- Primary central nervous system tumors in patients with multiple sclerosis.BMC neurology · 2025Observational
- Hyperprolactinemia as a manifestation of multiple sclerosis attack.BMJ neurology open · 2025Article
- Prolactin: Friend or Foe in Central Nervous System Autoimmune Inflammation?International journal of molecular sciences · 2016Review
- Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.Pituitary · 2016Article
- Relationship between Prolactin Plasma Levels and White Matter Volume in Women with Multiple Sclerosis.Mediators of inflammation · 2015Article
- Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients.Clinical reviews in allergy & immunology · 2012Article
- Sex-related factors in multiple sclerosis susceptibility and progression.Nature reviews. Neurology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a T-cell autoimmune disease of the central nervous system (CNS). Predominance of women in autoimmune diseases suggests that sex hormones may play a role in disease susceptibility. A possible role for prolactin, a neuroendocrine peptide with powerful immunomodulatory properties, is suggested in MS. We describe the case of a 32-year-old man affected by relapsing-remitting MS who experienced the first MS clinical event during the development of a prolactin-secreting adenoma and the only two MS relapses during adenoma recurrence. Prolactin may have facilitated the inflammatory process and triggered MS clinical attacks, suggesting a role of prolactin in immunomodulation and therefore in autoimmune disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.